Aardvark Therapeutics (NASDAQ:AARD) Coverage Initiated by Analysts at Cantor Fitzgerald

Research analysts at Cantor Fitzgerald initiated coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a report released on Monday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $50.00 price target on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 393.58% from the company’s previous close.

Aardvark Therapeutics Trading Up 6.4 %

NASDAQ:AARD opened at $10.13 on Monday. Aardvark Therapeutics has a 1 year low of $9.21 and a 1 year high of $19.58.

Insider Activity

In other news, CEO Tien-Li Lee purchased 16,542 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the transaction, the chief executive officer now directly owns 1,496,175 shares in the company, valued at $23,938,800. This represents a 1.12 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CFO Nelson Sun purchased 10,000 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was purchased at an average price of $16.00 per share, with a total value of $160,000.00. Following the transaction, the chief financial officer now owns 99,484 shares of the company’s stock, valued at approximately $1,591,744. This represents a 11.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.